A Study to Assess the Clinical Profile of Patients in Spain With Moderate to Severe Psoriasis.
NCT ID: NCT01262534
Last Updated: 2013-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1042 participants
OBSERVATIONAL
2010-10-31
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating Management of Patients With Moderate and Severe Psoriasis
NCT00894777
Clinical Assessment and Psychosocial Impact of Psoriasis
NCT01964443
Impact of the Mediterranean Diet on Patients with Psoriasis
NCT06257641
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
NCT02239666
Therapeutic Education Program in Psoriasis
NCT02310204
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Clinical profile of patients Comorbidities and associated type of treatments will be collected.
Clinical profile of patients
Comorbidities and associated type of treatments will be collected.
2
Quality of Life The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire to analyze the overall quality of life of patients and Dermatology Life Quality Index (DLQI) to analyze the quality of life of patients in dermatological terms).
Quality of Life
The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire, to analyze the overall quality of life of patients, and Dermatology Life Quality Index (DLQI), to analyze the quality of life of patients, in dermatological terms).
3
Patient Preferences about treatment Patient Benefit Index (PBI) for treatment to record patient preferences regarding psoriasis treatment.
Patient Preferences about treatment
Patient Benefit Index (PBI), for treatment to record patient preferences regarding psoriasis treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clinical profile of patients
Comorbidities and associated type of treatments will be collected.
Patient Preferences about treatment
Patient Benefit Index (PBI), for treatment to record patient preferences regarding psoriasis treatment.
Quality of Life
The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire, to analyze the overall quality of life of patients, and Dermatology Life Quality Index (DLQI), to analyze the quality of life of patients, in dermatological terms).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with psoriasis at least 6 months before the visit
* Diagnosed with moderate to severe psoriasis
* Who have been treated or not for moderate to severe psoriasis
* For whom the medical history dating back at least 6 months can be accessed
* the patient's legal representative has signed informed consent, stating that the patient understands the study purpose and requirements and grants the patient consent to participate in the study
Exclusion Criteria
* With any type of difficulty understanding the questions in the DLQI, SF-36 and PBI questionnaires
* Who and/or whose legal representative refuses to grant written, informed consent to participate in the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen-Cilag, S.A.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janssen-Cilag S.A. (formerly Janssen Sp) Clinical Trial
Role: STUDY_DIRECTOR
Janssen-Cilag, S.A.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CNTO1275PSO4013
Identifier Type: OTHER
Identifier Source: secondary_id
CR017545
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.